For prostate cancer, an anti-prostate-specific antigen (PSA) autoantibody could serve as a diagnostic biomarker (since PSA is a FDA-approved prostate cancer diagnosis biomarker, although it has clearly established limitations, but is routinely used in clinics), and may mediate anti-cancer effects (141). The gene discussed is KLK3; the disease is prostate carcinoma.